Floatz logo

Niraparib

Castration-Resistant Prostate Carcinoma

Explore 215 assets in Castration-Resistant Prostate Carcinoma →
Floatz Rating
B62/100
Confidence
Indicative
v0.2
Sponsor
Latin American Cooperative Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06527690CT.gov
Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer
—Withdrawn———
NCT06329830CT.gov
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
—Withdrawn———
NCT05689021CT.gov
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
—Active Not Recruiting———
NCT04592237CT.gov
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
—Active Not Recruiting———
NCT03903835CT.gov
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
—Recruiting———
NCT03748641CT.gov
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
—Active Not Recruiting———
NCT03431350CT.gov
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
—Active Not Recruiting———
NCT03076203CT.gov
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Castration-Resistant Prostate Carcinoma

AssetSponsorPhaseRating
Niraparib (this asset)Latin American Cooperative Oncology GroupP3B · 62
DarolutamideBayerP4BBB
EnzalutamideProstate Cancer Clinical Trials ConsortiumP4BBB
PrednisoloneDing-Wei YeP4BBB
CabozantinibRana McKay, MDP3BB
MevrometostatProstate Cancer Clinical Trials ConsortiumP3BB
Radium Ra-223University of California, San FranciscoP4BB
AbirateroneAstraZenecaP4BB
PrednisoneJanssen Research & Development, LLCP4BB

+42 more in the Castration-Resistant Prostate Carcinoma cohort

Other indications for Niraparib

IndicationSponsorPhaseRating
Breast Carcinoma—P3BB · 67
Ovarian Carcinoma—P4BB · 66
Ovarian Neoplasm—P4BB · 66

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Niraparib in Castration-Resistant Prostate Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/niraparib-castration-resistant-prostate-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →